Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

American Cancer Society announces new research, training grants for fiscal year 2013

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.

9 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Pancreatic Cancer Action Network researchers to participate in Rally for Medical Research

Researchers and advocates from the Pancreatic Cancer Action Network will join nearly 200 national organizations today in demonstrating their concern about the impact of sequestration on cancer research during the Rally for Medical Research at 11 AM on the steps of the Carnegie Library in Washington, D.C.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg - a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach - announced today that it will be presenting four abstracts at the AACR Annual Meeting 2013, in Washington, D.C.

8 Apr 2013

Anirban Maitra to lead pancreatic cancer research at UT MD Anderson Cancer Center

Anirban Maitra, M.B.B.S., a pre-eminent expert in the genetics of pancreatic cancer and the development of targeted therapies for the disease, will lead research at a new center at The University of Texas M.D. Anderson Cancer Center devoted to this highly lethal cancer.

5 Apr 2013

Men with Lynch syndrome face increased lifetime risk of prostate cancer

Men with an inherited genetic condition called Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Researchers validate metabolomic analysis as new diagnostic method for pancreatic cancer

A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.

30 Mar 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.

28 Mar 2013

New study associates commonly used diabetes drugs with pancreatic cancer risk

ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida.

28 Mar 2013

Pancreatic cancer cells' growth are fueled by metabolic pathway, scientists find

Dana-Farber Cancer Institute scientists and colleagues have discovered that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.

28 Mar 2013

Researchers discover protein that play role in spread of pancreatic cancer

Researchers at the University of North Carolina at Chapel Hill have discovered that a protein found in the cells surrounding pancreatic cancers play a role in the spread of the disease to other parts of the body.

26 Mar 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

TGen effort combines fundraising, gardening to combat pancreatic cancer

More northwest Ohio garden centers this spring are teaming up with an Arizona-based biomedical research organization to fight pancreatic cancer through the sale of purple flowers, which symbolize the nation's fourth leading cause of cancer death.

20 Mar 2013

IU researchers awarded $3.2 million grant to develop new treatments for pancreatic cancer

Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.

14 Mar 2013

Bitter melon juice restricts ability of pancreatic cancer cells to metabolize glucose

A University of Colorado Cancer study published this week in the journal Carcinogenesis shows that bitter melon juice restricts the ability of pancreatic cancer cells to metabolize glucose, thus cutting the cells' energy source and eventually killing them.

13 Mar 2013

Pancreatic Cancer News and Research

Further Reading

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

American Cancer Society announces new research, training grants for fiscal year 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Pancreatic Cancer Action Network researchers to participate in Rally for Medical Research

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Anirban Maitra to lead pancreatic cancer research at UT MD Anderson Cancer Center

Men with Lynch syndrome face increased lifetime risk of prostate cancer

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Researchers validate metabolomic analysis as new diagnostic method for pancreatic cancer

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

New study associates commonly used diabetes drugs with pancreatic cancer risk

Pancreatic cancer cells' growth are fueled by metabolic pathway, scientists find

Researchers discover protein that play role in spread of pancreatic cancer

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

TGen effort combines fundraising, gardening to combat pancreatic cancer

IU researchers awarded $3.2 million grant to develop new treatments for pancreatic cancer

Bitter melon juice restricts ability of pancreatic cancer cells to metabolize glucose

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News